Literature DB >> 14661902

Visual field defects in pediatric patients on vigabatrin monotherapy.

Francisco J Ascaso1, María J Lopez, José A Mauri, José A Cristobal.   

Abstract

UNLABELLED: Vigabatrin (GVG) is an effective antiepileptic drug used for treating partial seizures in adults and children. Over the last years, an increasing number of articles have been published reporting visual field defects (VFD) associated with GVG therapy in adults. To date, however, only an small number of pediatric patients have been reported. This paper is a retrospective review of clinical review to evaluate the prevalence and features of VFD in pediatric patients on GVG monotherapy.
METHODS: Fifteen children, on GVG therapy in the Department of Child Neurology, underwent visual field examination by static threshold automated perimetry using the Humphrey Field Analyzer Program 30-2. The age of these patients ranged from 6 to 18 years (12.4 +/- 3.6 years), 10 of them being male and five female.
RESULTS: Three patients (20%) on GVG monotherapy showed VFD. These consisted in localised, bilateral, and relatively symmetrical, nasal field loss, with relative preservation of the temporal field within the central 30 degree area.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14661902     DOI: 10.1023/a:1026237730283

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  26 in total

1.  Visual field constriction in children treated with vigabatrin.

Authors:  S Vanhatalo; L Pääkkönen; I Nousiainen
Journal:  Neurology       Date:  1999-05-12       Impact factor: 9.910

2.  Vigabatrin-associated retinal cone system dysfunction.

Authors:  A Roubertie; H Bellet; B Echenne
Journal:  Neurology       Date:  1998-12       Impact factor: 9.910

3.  Severe persistent visual field constriction associated with vigabatrin. Reaction might be dose dependent.

Authors:  I C Wong; G E Mawer; J W Sander
Journal:  BMJ       Date:  1997-06-07

4.  Severe persistent visual field constriction associated with vigabatrin. Patients taking vigabatrin should have regular visual field testing.

Authors:  N Blackwell; J Hayllar; G Kelly
Journal:  BMJ       Date:  1997-06-07

5.  Severe persistent visual field constriction associated with vigabatrin.

Authors:  T Eke; J F Talbot; M C Lawden
Journal:  BMJ       Date:  1997-01-18

6.  Characteristics of a unique visual field defect attributed to vigabatrin.

Authors:  J M Wild; C Martinez; G Reinshagen; G F Harding
Journal:  Epilepsia       Date:  1999-12       Impact factor: 5.864

7.  Outer retinal dysfunction in patients treated with vigabatrin.

Authors:  C F Arndt; P Derambure; S Defoort-Dhellemmes; J C Hache
Journal:  Neurology       Date:  1999-04-12       Impact factor: 9.910

Review 8.  Clinical approach to the management of intractable epilepsy.

Authors:  J Aicardi
Journal:  Dev Med Child Neurol       Date:  1988-08       Impact factor: 5.449

9.  Visual field defects associated with vigabatrin therapy.

Authors:  M C Lawden; T Eke; C Degg; G F Harding; J M Wild
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

10.  Visual impairment in children with epilepsy treated with vigabatrin.

Authors:  V Gross-Tsur; E Banin; E Shahar; R S Shalev; E Lahat
Journal:  Ann Neurol       Date:  2000-07       Impact factor: 10.422

View more
  1 in total

Review 1.  Vigabatrin.

Authors:  James W Wheless; R Eugene Ramsay; Stephen D Collins
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.